AbCellera Biologics (ABCL) Long-Term Debt Issuances (2020 - 2024)
AbCellera Biologics (ABCL) posted Long-Term Debt Issuances of $5.9 million for Q4 2024, up 90.17% on a QoQ basis from $3.1 million in Q3 2024, and up 17.28% year-over-year from $5.0 million in Q1 2024.
AbCellera Biologics (ABCL) Long-Term Debt Issuances (2020 - 2024) Analysis & Trends
AbCellera Biologics' Long-Term Debt Issuances history runs 5 years deep, the most recent figure standing at $5.9 million for Q4 2024.
- Quarterly Long-Term Debt Issuances rose 17.28% year-over-year to $5.9 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $13.5 million (up 16.46% YoY) and the FY2025 annual result came in at $29.7 million, up 120.26% from the prior year.
- Long-Term Debt Issuances was $5.9 million for Q4 2024 at AbCellera Biologics, up from $3.1 million in the prior quarter.
- Across five years, Long-Term Debt Issuances topped out at $16.2 million in Q1 2020 and bottomed at -$662000.0 in Q2 2020.
- A 5-year average of $2.9 million and a median of $1.9 million in 2021 frame the typical range for Long-Term Debt Issuances.
- Annual changes were most pronounced in 2021 — Long-Term Debt Issuances jumped 12728.57% — and 2022, when it plunged 80.97%.
- AbCellera Biologics' Long-Term Debt Issuances stood at $974000.0 in 2020, then jumped by 88.3% to $1.8 million in 2021, then plunged by 80.97% to $349000.0 in 2022, then jumped by 1341.26% to $5.0 million in 2023, then gained by 17.28% to $5.9 million in 2024.
- Business Quant data shows ABCL's Long-Term Debt Issuances at $5.9 million in Q4 2024, $3.1 million in Q3 2024, and $2.4 million in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | AbCellera Biologics | 1.72 Bn | 1.72 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 5.90 Mn |
| Dec 31, 2024 | 5.90 Mn |
| Sep 30, 2024 | 3.10 Mn |
| Sep 30, 2024 | 3.10 Mn |
| Jun 30, 2024 | 2.37 Mn |
| Jun 30, 2024 | 2.37 Mn |
| Mar 31, 2024 | 2.12 Mn |
| Mar 31, 2024 | 2.12 Mn |
| Dec 31, 2023 | 5.03 Mn |
| Dec 31, 2023 | 5.03 Mn |
| Sep 30, 2023 | 6.56 Mn |
| Sep 30, 2023 | 6.56 Mn |
| Dec 31, 2022 | 349,000.00 |
| Dec 31, 2022 | 349,000.00 |
| Sep 30, 2022 | 231,000.00 |
| Sep 30, 2022 | 231,000.00 |
| Jun 30, 2022 | 234,000.00 |
| Jun 30, 2022 | 234,000.00 |
| Mar 31, 2022 | 1.94 Mn |
| Mar 31, 2022 | 1.94 Mn |